Member Info for Hulver

Somewhat out of main focus: but can anyone shed any further light on the 'miracle negotiator' that was soon to join Hemo in late 2021, alongside Dr Alan Walts, who would appear to still be engaged on the basis of his inclusion on Vlad's presentation slides at the September, Boston pitch for Bait Biotechnology.

https://total-market-solutions.com/2021/10/hemogenyx-pharmaceuticals_oct_2021/

Hemo mice are smart!

Haywain,

...and I'm predicting that in years to come similar will be written about (at least) one of HEMO's current team of younger scientists.

A fountain of cures and a hotbed of talent. It's quite obvious where this company is headed.

Interestingly, this investment professional at Heligan seems to like Hemo:

https://uk.linkedin.com/in/simon-heath-39b461117?trk=public_profile_browsemap-profile

Will this be patentable?

RNS downplayed(?) it as mRNA mixed with a polymer & solvent.

Thanks for clarifying. Me too, but not for want of trying.

I guess there could be some genuine large sellers then.

Can anyone suggest answers to the following:

- why has there never been any TR1s here - either on acquiring or exiting? I thought holdings in excess of 3% had to be disclosed, and any subsequent movement up or down that goes through the next whole percentage point.

- are certain shareholders exempt from the requirement to disclose in a TR1?

- can several shareholders/entities work in collusion to collectively hold >3% without making disclosure (eg 10 related entities owning 2% each)? It seems that was what Ron Bauer and co were accused of in the US, and at least two of their number (Bauer and Auringer) were investors here in the early days, when initial admission was 3p; and in one of the video calls (probably about 18 months ago or more) Vlad indicated that they no longer knew how their shares were held or whether any had been sold at the time of the video call, since they had been moved out of their names into a custodian's account - perhaps they were still there. From reports their strategy was to accumulate large shareholdings in low volume stocks.

Interesting...

Yesterday broker would not accept a limit trade to be placed, something like 'price too far away from current price'

Today - happy to accept limit trades for a bigger difference. Same number of shares. Why is that?

Needless to say, I have held off.

Last time Vlad considered he had won was when he extracted himself from Globalco deal, buying out the IP element that Globalco had introduced.

so does seem to suggest that he may have withdrawn from Prevail.

'accelerating clinical' sort of implies something new too. But what would be 'excruciatingly difficult' for him - giving up control of HEMO CAR-T perhaps?

As an aside I note that Jessica Jang, ex Collectis - 3 years, has left Hemogenyx in Feb 2024 after just 11 months - which seems a bit of a blow.

That makes more sense - thanks

Does the following help to make any sense of what happened Friday (and earlier since start of 2024 and previous spikes):

The conversions by Mint under the convertible loan note were:

25 February 2021: 13,131,313 new ordinary shares at a conversion price of £0.0495

26 March 2021: 14,285,714 new ordinary shares at a conversion price of £0.063

16 April 2021: 24,547,803 new ordinary shares at a conversion price of £0.0387

26 April 2021: 29,850,746 new ordinary shares at a conversion price of £0.03015

5 May 2021: 22,222,222 new ordinary shares at a conversion price of £0.0225

Is it just coincidence that the bid price opened at 6.30 p (the highest issue price to Mint)?

Is it just coincidence that 2.25p and the 3.87p approx were sticking points on the way back up? We currently rest around 3.87p.

Since Vlad crashed the SP with the 1.5p take out have Mint remained sitting on these shareholdings from their CLN conversions in teh background until now when they can realise them at a profit?

Has Friday seen Mint clear the bulk of their shareholding - highest price first?

Let's not forget that Hemo have Dr Koen van Besien as clinical director. CAR-T clinical trials is his business.

https://ashpublications.org/ashclinicalnews/news/6486/UH-Selects-Koen-van-Besien-as-Hematology-Chief-and

They also developed HEMO-CAR-T with UPenn, and its hospital/centre too is regularly conducting CAR-T trials.

Hence, I don't expect there to be any delay in finding trial candidates.

Clearly for AML sufferers CAR-T offers a real hope of a future.

Thursday's child...

The following link describes Prevails last investment as PIPE.

https://www.cbinsights.com/company/hemogenyx/financials

Then considering the RNS re: Prevail

https://hemogenyx.com/investors/investors/announcements/announcement/2023/hemogenyx-pharmaceuticals-announces-strategic-investment-from-prevail-partners-llc/

Does the sentence:

“The agreement governing the subscription (the “Subscription Agreement”) contains customary warranties from the Company and Prevail Partners.”

suggest that there is a restriction on Prevail selling there first issue of shares.

So in my view this is pointing to more of the same type of funding for CAR-T, CDX and CBR (there is plenty to be done - £10m may not be enough fo two years, but perhaps we may have shorter gaps between future PIPE funding rounds, with fair value revaluations at each point) .

Remember also that Dr Alan Walts has been involved for a couple of years now - in the past he's also been involved in funding rounds for other biotech companies, on occasion in the range of US$20m.

SP will still be based on supply and demand of unrestricted shares. The potential supply would become 'limited' though (until the PIPE shares are out of restriction). If people want in they will need to pay.

Needless to say, my shareholding is not for sale either.

I found the attached document in relation to PIPE funding.

https://www.sec.gov/info/smallbus/gbfor25_2006/pinedo_tanenbaum_pipefaq.pdf

{If link does not work google 'PIPE Funding Tenenbaum FAQ' to find it. As well as explaining PIPE Funding it also contains a final paragraph on 'death spiral' finance - if only HEMO would have had that warning two years ago}

“During the black-out period, the purchasers will have limited liquidity, as they will not be able to avail themselves of the resale registration statement to resell the securities purchased in the transaction.”

That is essentially what we want - a PIPE funding round, with a (two year) resale restriction by the new participants.

Now that would be funny.

But HEMO has competition on the GBM brain cancer front; the following has been reported most recently:

Australian of the Year Award Winners 2024 - Prof. Richard Scolyer (he himself, his own GBM patient) and Prof. Georgina Long of the Melanoma Institute of Australia.

https://www.bbc.co.uk/news/world-australia-67870595

https://melanoma.org.au/news/melanoma-science-race-against-brain-cancer-national-press-club/

Encouraging developments that help support the potential of HEMO's science - but HEMO needs to be moving along, with new funding.

Slide 15:

Summary

• A novel proprietary technology.

• Proof of Concept has been established

• Directly applicable to the US Department of Defense and HHS objectives.

• Technology is ready for translational science to develop and test products.

• BAIT Biotechnology has the facility and people to execute a program

Slide 14:

Current Product Candidates

{remember these relate only to the plan for BAIT Biotechnology)

CBR

• Ebola, Marburg (Filoviridae family) – POC in vitro using synthetic non-replicating virus.

• SARS-CoV-2 (Coronaviridae family) – POC in vitro using synthetic non-replicating virus; BSL3 for replicating virus in works.

• Influenza A, B (Orthomyxoviridae family) – POC in works.

• HSC-derived CBR-programmed microglia for glioblastoma multiforme (GBM).

BME

• Ebola and Marburg (Filoviridae family) – POC in vitro using synthetic non-replicating virus.

• Venezuelan and Western Equine Encephalitis (Alpha viruses) – POC in works (designed).

• Nipah and Hendra (Paramyxoviridae family) – POC in works (designed).

• Lassa (Arenaviridae family) – POC in works (designed).

• Influenza A, B (Orthomyxoviridae family) – POC in works (designed).

• SARS-CoV-2 (Coronaviridae family) – POC in vitro using synthetic non-replicating virus.

Slide 12:

CBR/BME Administration for Viral Infections

{Several charts that cannot be made out}

Advantages:

• Self-replication mRNA.

- longer lasting expression

- higher density of CBR

- higher production of BME

• Targeted polymer biodegradable nanoparticles

- cell specificity

- reduced immunogenicity

- improved handling and deployment

Slide 13:

CBR Administration for Brain Tumors

Depicts two diagrams:

1. In vivo proof of concept

Model: Systemic migration and engraftment of human WBC in immunodeficient mice

2. Human Administration concept

Microglia specific expression of CBR can treat glioblastoma multiforme (GBM) patients.

Advantages:

• Edited autologous HSC derived microglia

- Cross Blood Brain Barrier (BBB)

- No rejection

- Long anti-cancer surveillance

- Unlimited source of CBR programmed cells

Slide 11:

CBR Proof of Concept

Proof of Concept

• Demonstrated in vitro that immune cells programmed aith CBR against SARS-CoV-2 selectively consume live synthetic virus that carries (i.e. is pseudo-typed with) the Spike envelope protein of SARS-CoV-2 virus on its surface.

• Demonstrated that the function of CBR was not affected by known mutations of the Spike protein.

• Currently conducting in vitro and in vivo tests in BSL-3 facility to demonstrate that CBR can be used against infectious replicating SARS-Cov-2 virus.

• Identified and optimized a target protein (bait) that is being incorporated into a multipurpose CBR-based and BME-based therapeutic capable of treating multiple viruses that belong to different viral families instead of having to make a separate CBR or BME construct for every virus. Among the targeted viruses are Dengue and Zika (Faviviridae family), Ebola and Marburg (Filoviridae family) and Chikungunya (Togaviridae family).

Extensive Scope for Expanding Applications

• Expand potential use of CBR and BME to treat bacterial infections and cancer.

• Several modifications of the original design of CBRs enable the generation of cell-independent constructs which can be used as off-the-shelf drugs for the treatment of both viral infections and cancers – BME and AME.